Kite Reports 73 Percent of Patients Achieved MRD Negative Complete Remission in Updated Analysis From Phase 1 ZUMA-3 CAR-T Trial of KTE-C19 in Adult Patients With High Burden Relapsed/Refractory Acute Lymphoblastic Leukemia

Kite Receives U.S. Food and Drug Administration Priority Review for Axicabtagene Ciloleucel

UroGen Pharma Appoints Fred E. Cohen, MD, to its Board of Directors

UroGen Pharma Announces Closing of Initial Public Offering and Exercise of Underwriters’ Option

Capricor Therapeutics Announces Private Placement of Common Stock

Capricor Therapeutics Announces Positive Six-Month Results from the Randomized Phase I/II HOPE Clinical Trial in Duchenne Muscular Dystrophy

UroGen Pharma Welcomes New Board Member Kate Falberg

Sienna Biopharmaceuticals Announces $40 Million Series B Financing

Kite Wins ‘Clinical Trial Result of the Year’ for its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 Clinical and Research Excellence Awards

UroGen Pharma Announces Enrollment of First Patient in Phase 3 Clinical Trial of MitoGel™ for Treatment of Low-Grade Upper Tract Urothelial Carcinoma

Kite Presents Ongoing Response Rate in Plenary Session from its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 American Association of Cancer Research Annual Meeting

Kite Completes Submission of U.S. Biologics License Application (BLA) for Axicabtagene Ciloleucel as the First CAR-T Therapy for the Treatment of Patients With Aggressive Non-Hodgkin Lymphoma (NHL)

Richard Peterson Joins Sienna Biopharmaceuticals As Chief Financial Officer

Hubble Contacts Wants To Do For Contact Lenses What Harry’s Did For Razors

Cell Design Labs Announces Issuance of a Broad Patent for Programmable CAR-T Cells to Treat Cancer and Other Diseases

Kite Pharma Highlights Publication from the National Cancer Institute Demonstrating Durable Complete Remissions in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Following Low Dose Conditioning Chemotherapy and Anti-CD19 CAR T-Cell Therapy

Kite Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Hubble raises $16.5 million to deliver affordable daily contact lenses

Kite Announces Positive Topline Primary Results of Axicabtagene Ciloleucel from First Pivotal CAR-T Trial in Patients with Aggressive Non-Hodgkin Lymphoma

Former Allergan Chief David Pyott Signs on as Special Advisor to Sienna Biopharmaceuticals

Cell Design Labs’ Scientific Founder Co-Authors Review Article Illustrating Power and Potential of Engineered Human Cells to Treat Cancer

Kite Pharma and Fosun Pharma Establish Joint Venture in China to Develop and Commercialize Autologous T-Cell Therapies to Treat Cancer

Kite Pharma Establishes a Strategic Partnership With Daiichi Sankyo to Develop and Commercialize Axicabtagene Ciloleucel (KTE-C19) in Japan

Kite Pharma Submits Investigational New Drug (IND) Application for KITE-718, an Investigational Next Generation T-Cell Receptor (TCR) Therapy Targeting Cancer Antigens MAGE A3 and MAGE A6

Kite Pharma Announces Successful Defense of Roberts Patent and Intent to Appeal U.S. Patent and Trademark Office Decision on a Narrow Patent Focused on Select CD28 CAR-T Products